• Explore /
  • Poster
  • / Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).

Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).

Abstract Poster

Authors

Daniel Catenacci

Daniel V.T. Catenacci

University of Chicago Medical Center and Biological Sciences, Chicago, IL

Daniel V.T. Catenacci , Kian Huat Lim , Hope Elizabeth Uronis , Yoon-Koo Kang , Matthew C.H. Ng , Philip Jordan Gold , Peter C. Enzinger , Keun Wook Lee , Jill Lacy , Se Hoon Park , Jennifer Yen , Justin Odegaard , Aleksandra Franovic , Jan E. Baughman , Aisha Wynter-Horton , Francine Chen , Paul A. Moore , Tony Wu , Jan Kenneth Davidson-Moncada , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Clinical Trial Registration Number

NCT02689284

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 65)

DOI

10.1200/JCO.2019.37.4_suppl.65

Abstract #

65

Poster Bd #

G15

Abstract Disclosures

Similar Posters

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Timothy Jay Price